{"publication_id":"3f0afbf6-e835-4b75-ae70-8dfca79bcb14","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Impact of aging on the pharmacokinetic profile of everolimus in male mice","doi":"10.1186/s40360-025-01079-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α","doi":"10.3389/fimmu.2021.753412","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma","doi":"10.3727/096504022X16418911579334","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma","doi":"10.3389/fonc.2022.874091","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Predicting clinical response to everolimus in ER+ breast cancers using machine-learning","doi":"10.3389/fmolb.2022.981962","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus","doi":"10.3389/fonc.2020.01047","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors","doi":"10.1007/s11547-022-01506-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Everolimus Aging Study","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma","doi":"10.1159/000516277","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer","doi":"10.1007/s00280-011-1653-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer","doi":"10.1186/bcr3634","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis","doi":"10.1007/s12325-013-0060-1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study","doi":"10.1002/cam4.2460","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer","doi":"10.1001/jamaoncol.2018.2262","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"LB2. TORC1 Inhibition with RTB101 as a Potential Pan-Antiviral Immunotherapy to Decrease the Incidence of Respiratory Tract Infections Due to Multiple Respiratory Viruses in Older Adults","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer","doi":"10.1056/nejmoa1109653","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)","doi":"10.1200/jco.2005.23.16_suppl.7104","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study.","doi":"10.1200/jco.2012.30.15_suppl.556","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer","doi":"10.1158/0008-5472.can-06-4490","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma","doi":"10.1159/000496984","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma","doi":"10.1200/jco.2014.58.3401","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis","doi":"10.3109/10428190903486220","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)","doi":"10.3233/kca-170020","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).","doi":"10.1182/blood.v110.11.121.121","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"LB TORC Inhibition 2019","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Everolimus and or Exercise to Prevent 2026","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Study to Determine the Safety 2012","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Everolimus Aging Study 2026","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Resistance Training and Rapamycin n.d.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Ioannidis 2005","doi":"10.1371/journal.pmed.0020124","risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}